Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis

OBJECTIVES: The optimal duration of anti-PD-1 for cancer therapy has not been tested, especially when using combination therapy. Epidermal growth factor receptor (EGFR) pathway blocker was the top compound that enhanced T-cell killing of tumor cells in a high-throughput immune-oncology screen, possi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Hsiang-Fong, Huang, Huai-Cheng, Liao, Bin-Chi, Hong, Ruey-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703826/
https://www.ncbi.nlm.nih.gov/pubmed/36443704
http://dx.doi.org/10.1186/s12885-022-10343-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703826/
https://www.ncbi.nlm.nih.gov/pubmed/36443704
http://dx.doi.org/10.1186/s12885-022-10343-7

Ejemplares similares